13F

Stock

Theriva Biologics, Inc.

TOVX · held by 21 managers

Reported value

$272.4K

Holders

21

+2 new · −0 exited

Holders’ est. mark

−$17

Price effect on 3 books still in the name

Largest holder

$53.7K

Vanguard

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
Vanguard255.7K$53.7KHeld
GEODE CAPITAL MANAGEMENT, LLC212.1K$44.6KHeld
MORGAN STANLEY200K$42.1KNew
UBS Group AG191.4K$40.2KHeld
Ikarian Capital, LLC112.1K$23.6KHeld
TWO SIGMA SECURITIES, LLC42.9K$9.03KHeld
TWO SIGMA INVESTMENTS, LP42.3K$8.91KHeld
DRW Securities, LLC41.7K$8.78KHeld
XTX Topco Ltd39.4K$8.3KHeld
StoneX Group Inc.37.2K$7.83KHeld
BARCLAYS PLC32.6K$6.85KNew
BANK OF AMERICA CORP /DE/31.1K$6.54K−$15Added$6.51K
BOOTHBAY FUND MANAGEMENT, LLC27.6K$5.82KHeld
SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC15K$3.16KHeld
BlackRock, Inc.7.5K$1.58KHeld
CITIGROUP INC6.19K$1.3KHeld
OSAIC HOLDINGS, INC.448$93Held
SBI Securities Co., Ltd.59$12Held
IFP Advisors, Inc11$2−$2Cut−$2
Newbridge Financial Services Group, Inc.5$1Held
DANSKE BANK A/S1$0$0Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.